Form 4: Opaleye Management Increases Stake in Alpha Cognition

Major shareholder Opaleye Management Inc. acquired 24,376 additional shares of Alpha Cognition Inc., signaling continued institutional confidence.

Summary

• Opaleye Management Inc., a 10% owner of Alpha Cognition Inc. (ACOG), purchased a total of 24,376 shares of common stock in the open market.
• The transactions occurred over two consecutive days: May 20 and May 21, 2026.
• On May 20, 2026, 8,431 shares were purchased at a price of $5.89 per share.
• On May 21, 2026, 15,945 shares were purchased at a price of $5.70 per share.
• Following these acquisitions, Opaleye Management indirectly beneficially owns 2,620,369 shares through Opaleye, L.P. and a separately managed account.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development because a sophisticated 10% owner is actively increasing their position in the open market, suggesting they believe the stock is undervalued.

Positives

• Demonstrates strong institutional support from a major 10% owner.
• Total investment of approximately $140,545 in new capital over a 48-hour period.
• The reporting person increased their total position to over 2.6 million shares, indicating long-term commitment.

Negatives

• The purchase price on the second day ($5.70) was lower than the first day ($5.89), reflecting short-term downward price movement during the accumulation period.

Risks

• Concentration risk, as a single institutional entity holds a significant portion of the outstanding shares.
• Market volatility affecting the valuation of the common stock, as evidenced by the price fluctuation between transaction dates.

Future Outlook

While the filing does not provide specific guidance, the continued accumulation of shares by a 10% owner suggests a positive outlook on the company's valuation or upcoming milestones.

Management Comments

• Opaleye Management Inc. disclaims beneficial ownership of the shares reported except to the extent of its pecuniary interest therein.

Industry Context

StockSavvy.ai notes that consistent open-market purchases by 10% owners in the biotechnology sector are often viewed as a bullish indicator, potentially preceding clinical data readouts or strategic corporate developments.

Comparison to Industry Standards

• Institutional ownership levels are consistent with other micro-cap biotech firms like Cassava Sciences or Anavex Life Sciences where specialized funds maintain large concentrated positions.
• The purchase size is relatively modest compared to major institutional rounds but significant for daily open-market volume in small-cap equities.

Related Party Transactions

• The reporting person is a 10% owner, making these transactions related-party acquisitions of equity securities.

Stakeholder Impact

• Shareholders may see this as a vote of confidence, potentially supporting the share price.
• The increased concentration of ownership gives Opaleye Management more influence over corporate matters.

Next Steps

• Monitor for additional Form 4 filings to see if Opaleye continues to accumulate shares.
• Watch for upcoming clinical or regulatory announcements from Alpha Cognition that may have prompted this buying activity.

Key Dates

Recommendation

Institutional buying is a positive sign, but investors should wait for broader fundamental catalysts or clinical updates before moving to a strong buy, as the company remains in a high-risk biotech development phase.

Keywords

Alpha Cognition, ACOG, Opaleye Management, Insider Buying, Form 4, Biotechnology, Institutional Investment, Common Stock